专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130045192A1 REAGENTS AND METHODS FOR DETECTING PNH TYPE II WHITE BLOOD CELLS AND THEIR IDENTIFICATION AS RISK FACTORS FOR THROMBOTIC DISORDERS 审中-公开
标题翻译：用于检测PNH II型白细胞的试剂和方法及其作为血栓病症风险因子的鉴定
公开(公告)号：US20130045192A1
公开(公告)日：2013-02-21
申请号：US13508909
申请日：2010-11-09
申请人： Mayur Movalia , Andrea Illingworth , Susan Faas McKnight , Russell P. Rother
发明人： Mayur Movalia , Andrea Illingworth , Susan Faas McKnight , Russell P. Rother
IPC分类号： G01N33/566 , A61P7/00 , A61K31/727 , A61P7/02 , A61K35/14 , A61K38/49
CPC分类号： G01N33/5094 , A61K31/352 , A61K31/56 , A61K31/727 , A61K35/19 , A61K38/196 , A61K38/4886 , C07K16/40 , G01N33/56972 , G01N33/6893 , G01N2800/226
摘要： The disclosure relates to methods for detecting PNH Type II cell populations in biological samples as well as methods for determining whether a patient is at an increased risk for developing thrombocytopenia or thrombosis based on the percentage of PNH Type II cells in the patient's blood. The disclosure also features reagents and conjugates for use in the methods.
摘要翻译：本公开涉及用于检测生物样品中PNH II型细胞群的方法，以及用于基于患者血液中PNH II型细胞的百分比来确定患者是否处于发生血小板减少症或血栓形成的风险增加的方法。本公开还涉及用于该方法的试剂和共轭物。

2. 发明申请

US20120321625A1 ANTIBODIES TO OX-2/CD200 AND USES THEREOF IN INHIBITING IMMUNE RESPONSES 有权
标题翻译： OX-2 / CD200的抗体及其在抑制免疫应答中的用途
公开(公告)号：US20120321625A1
公开(公告)日：2012-12-20
申请号：US13533546
申请日：2012-06-26
申请人： Russell P. Rother , Susan Faas McKnight
发明人： Russell P. Rother , Susan Faas McKnight
IPC分类号： A61K39/395 , A61K38/13 , A61K31/395 , A61P37/06
CPC分类号： C07K16/2803 , A61K39/39541 , A61K2039/505 , C07K2317/52 , A61K2300/00
摘要： This disclosure provides methods and compositions for inhibiting immune responses. The disclosure also provides methods and compositions for inhibiting graft rejection and promoting or prolonging graft survival.
摘要翻译：本公开提供了用于抑制免疫应答的方法和组合物。本公开还提供了用于抑制移植物排斥和促进或延长移植物存活的方法和组合物。

3. 发明授权

US08252285B2 Antibodies to OX-2/CD200 and uses thereof in inhibiting immune responses 有权
标题翻译： OX-2 / CD200的抗体及其在抑制免疫应答中的用途
公开(公告)号：US08252285B2
公开(公告)日：2012-08-28
申请号：US12670379
申请日：2008-07-25
申请人： Russell P. Rother , Susan Faas McKnight
发明人： Russell P. Rother , Susan Faas McKnight
IPC分类号： A61K39/395
CPC分类号： C07K16/2803 , A61K39/39541 , A61K2039/505 , C07K2317/52 , A61K2300/00
摘要： This disclosure provides methods and compositions for inhibiting immune responses. The disclosure also provides methods and compositions for inhibiting graft rejection and promoting or prolonging graft survival.
摘要翻译：本公开提供了用于抑制免疫应答的方法和组合物。本公开还提供了用于抑制移植物排斥和促进或延长移植物存活的方法和组合物。

4. 发明授权

US08637014B2 Antibodies to OX-2/CD200 and uses thereof in inhibiting immune responses 有权
标题翻译： OX-2 / CD200的抗体及其在抑制免疫应答中的用途
公开(公告)号：US08637014B2
公开(公告)日：2014-01-28
申请号：US13533546
申请日：2012-06-26
申请人： Russell P. Rother , Susan Faas McKnight
发明人： Russell P. Rother , Susan Faas McKnight
IPC分类号： A61K39/395
CPC分类号： C07K16/2803 , A61K39/39541 , A61K2039/505 , C07K2317/52 , A61K2300/00
摘要： This disclosure provides methods and compositions for inhibiting immune responses. The disclosure also provides methods and compositions for inhibiting graft rejection and promoting or prolonging graft survival.
摘要翻译：本公开提供了用于抑制免疫应答的方法和组合物。本公开还提供了用于抑制移植物排斥和促进或延长移植物存活的方法和组合物。

5. 发明申请

US20090220508A1 Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement 审中-公开
标题翻译：阵发性夜间血红蛋白尿患者由补体抑制剂治疗
公开(公告)号：US20090220508A1
公开(公告)日：2009-09-03
申请号：US12225040
申请日：2007-03-15
申请人： Leonard Bell , Russell P. Rother
发明人： Leonard Bell , Russell P. Rother
IPC分类号： A61K39/395
CPC分类号： C07K16/18 , A61K9/0019 , A61K31/7105 , A61K38/00 , A61K2039/505 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/565
摘要： Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH.
摘要翻译：厄洛珠单抗是抑制末端补体激活的C5的人源化单克隆抗体，在阵发性夜间血红蛋白尿（PNH）患者的小队列中，在初步的12周开放标签试验中显示出活性。本研究检查了在双盲，随机，安慰剂对照，多中心全球III期试验中，慢性eculizumab治疗是否可以减少血管内溶血，稳定血红蛋白水平，降低输血需求，提高生活质量。已经发现，通过减少血管内溶血，厄库珠单抗稳定了血红蛋白水平，降低了输血的需要，并改善PNH患者的生活质量。慢性eculizumab治疗似乎是PNH的安全有效的治疗方法。

6. 发明申请

US20120308559A1 METHOD OF TREATING HEMOLYTIC DISEASE 审中-公开
标题翻译：治疗HEMOLYTIC疾病的方法
公开(公告)号：US20120308559A1
公开(公告)日：2012-12-06
申请号：US13335518
申请日：2011-12-22
申请人： Leonard Bell , Russell P. Rother , Peter Hillmen
发明人： Leonard Bell , Russell P. Rother , Peter Hillmen
IPC分类号： A61K39/395 , A61P37/06 , A61P7/02 , A61P7/00
CPC分类号： A61K45/06 , A61K39/39541 , A61K2039/545 , A61K2300/00
摘要： Paroxysmal nocturnal hemoglobinuria or other hemolytic diseases are treated using a compound which binds to or otherwise blocks the generation and/or the activity of one or more complement components, such as, for example, a complement-inhibiting antibody.
摘要翻译：使用结合或以其它方式阻断一种或多种补体成分（例如补体抑制性抗体）的产生和/或活性的化合物治疗阵发性夜间血红蛋白尿或其它溶血性疾病。

7. 发明授权

US08282924B2 Hybrid antibodies 有权
标题翻译：杂交抗体
公开(公告)号：US08282924B2
公开(公告)日：2012-10-09
申请号：US13088633
申请日：2011-04-18
申请人： Russell P. Rother , Dayang Wu
发明人： Russell P. Rother , Dayang Wu
IPC分类号： C07K16/46 , C12P21/00
CPC分类号： C07K16/464 , C07K16/00 , C07K16/2851 , C07K2317/565 , C07K2317/567 , C07K2317/92
摘要： Hybrid antibodies and/or hybrid antibody fragments and methods of making them are provided. In one embodiment the hybrid antibodies and/or hybrid antibody fragments 5 contain heavy and/or light variable regions that contain two or more framework regions derived from at least two antibodies. In another embodiment, at least two of the framework regions are classified in the same germline gene family. In one embodiment, at least two framework regions are classified in the same germline gene family member. The hybrid antibodies or hybrid antibody fragments may contain human framework regions and 10 nonhuman CDRs.
摘要翻译：提供杂交抗体和/或杂交抗体片段及其制备方法。在一个实施方案中，杂合抗体和/或杂合抗体片段5含有含有两个或更多个衍生自至少两种抗体的框架区的重和/或可变区。在另一个实施方案中，框架区域中的至少两个被分类在相同的种系基因家族中。在一个实施方案中，将至少两个框架区域分类在相同的种系基因家族成员中。杂交抗体或杂合抗体片段可以含有人框架区和10个非人CDR。

8. 发明申请

US20110086040A1 METHOD OF TREATING HEMOLYTIC DISEASE 审中-公开
标题翻译：治疗HEMOLYTIC疾病的方法
公开(公告)号：US20110086040A1
公开(公告)日：2011-04-14
申请号：US12902617
申请日：2010-10-12
申请人： Leonard Bell , Russell P. Rother
发明人： Leonard Bell , Russell P. Rother
IPC分类号： A61K39/395 , A61P7/00
CPC分类号： A61K45/06 , A61K39/39541 , A61K2039/545 , A61K2300/00
摘要： Paroxysmal nocturnal hemoglobinuria or other hemolytic diseases are treated using a compound which binds to or otherwise blocks the generation and/or the activity of one or more complement components, such as, for example, a complement-inhibiting antibody.
摘要翻译：使用结合或以其它方式阻断一种或多种补体成分（例如补体抑制性抗体）的产生和/或活性的化合物治疗阵发性夜间血红蛋白尿或其它溶血性疾病。

9. 发明申请

US20100135992A1 Prolongation of Survival of an Allograft by Inhibiting Complement Activity 审中-公开
标题翻译：通过抑制补体活性延长同种异体移植物的存活
公开(公告)号：US20100135992A1
公开(公告)日：2010-06-03
申请号：US12224567
申请日：2007-03-02
申请人： Russell P. Rother , Hao Wang , Zheng Zhong
发明人： Russell P. Rother , Hao Wang , Zheng Zhong
IPC分类号： A61K39/395 , A61P43/00
CPC分类号： C07K16/18 , A61K31/16 , A61K31/365 , A61K31/573 , A61K38/13 , A61K2039/505
摘要： Methods of prolonging survival of allotransplanted cells, tissues or organs are presented. These methods are directed to administering to the allograft recipient an inhibitor of complement activity together with one or more immunosuppressants and/or immunosuppressive methods. The inhibitor of complement activity is administered chronically. These methods have been determined to aid in preventing chronic rejection of allografts. These methods can additionally be used in cases in which the recipient has been presensitized to the allograft or in which there is an ABO mismatch between the allograft and the recipient.
摘要翻译：提出了延长移植细胞，组织或器官存活的方法。这些方法涉及向同种异体移植受体施用补体活性的抑制剂以及一种或多种免疫抑制剂和/或免疫抑制方法。补体活性抑制剂长期施用。已经确定了这些方法以帮助预防同种异体移植物的慢性排斥反应。这些方法可以另外用于接受者已经被同化异体移植或同种异体移植物与受体之间存在ABO不匹配的情况。

10. 发明授权

US5562904A Retroviral transduction of cells using soluble complement inhibitors 失效
标题翻译：使用可溶性补体抑制剂逆转录病毒转导细胞
公开(公告)号：US5562904A
公开(公告)日：1996-10-08
申请号：US278550
申请日：1994-07-21
申请人： Russell P. Rother , Scott A. Rollins , James M. Mason , Stephen P. Squinto
发明人： Russell P. Rother , Scott A. Rollins , James M. Mason , Stephen P. Squinto
IPC分类号： C12N15/09 , A61K38/00 , A61K39/395 , A61K45/00 , A61K48/00 , A61P43/00 , C07K16/18 , C12P21/08 , B61K39/395
CPC分类号： C07K16/18 , A61K38/00
摘要： Methods and compositions are provided for facilitating gene therapy procedures involving the transduction of target cells with retroviral vector particles in the presence of complement containing body fluids. The administration of soluble complement inhibitor molecules to body fluids prevents the complement mediated inactivation of the retroviral vector particles, and provides a safety mechanism for such gene therapy procedures, as the action of soluble complement inhibitors is transient, and any retroviral vector particles present after the return of uninhibited complement activity will be inactivated. Preferred soluble complement inhibitors for use in the practice of the present invention include complement inhibitory anti-complement component mAbs (including complement inhibitory anti C5 antibodies).
摘要翻译：提供了方法和组合物，用于促进涉及在含补体的体液存在下用逆转录病毒载体颗粒转导靶细胞的基因治疗方法。向体液施用可溶性补体抑制剂分子可防止补体介导的逆转录病毒载体颗粒的失活，并为此类基因治疗程序提供安全机制，因为可溶性补体抑制剂的作用是暂时的，并且任何逆转录病毒载体颗粒存在于不受限制的补体活动的返回将被灭活。用于实施本发明的优选的可溶性补体抑制剂包括补体抑制性抗补体成分mAb（包括补体抑制性抗C5抗体）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式